In:
Journal of Pharmacy and Pharmacology, Oxford University Press (OUP), Vol. 69, No. 5 ( 2017-04-06), p. 525-528
Kurzfassung:
Iron chelation in the transfusion-dependent anaemias management is essential to prevent end-organ damage and to improve survival. Deferasirox is a once-daily orally active tridentate selective iron chelator which pharmacokinetic disposition could influence treatment efficacy and toxicity. Therapeutic drug monitoring is an important tool for optimizing drug utilization and doses. Methods A fully validated chromatographic method was used to quantify deferasirox concentration in plasma collected from paediatric patients with β-thalassaemia. Samples obtained after 5 days of washout or in naïve patients before and after 2, 4, 6 and 24 h drug administration were evaluated. Key findings Associations between variables were tested using the Pearson test. Twenty paediatric patients were enrolled; they were mainly men (13.65%), with median age of 6.35 years and body mass index of 15.45 kg/m2. Concerning pharmacokinetic parameters, a higher interindividual variability was shown. A positive, but not significant, correlation (r = 0.363; P = 0.115) was found between deferasirox area under the concentration curve over 24 h (AUC) and drug dose. Conclusions Monitoring plasma deferasirox concentrations appears beneficial for guiding appropriate patient treatment, enhancing effectiveness and minimizing toxicity.
Materialart:
Online-Ressource
ISSN:
2042-7158
,
0022-3573
Sprache:
Englisch
Verlag:
Oxford University Press (OUP)
Publikationsdatum:
2017
ZDB Id:
2041988-0
ZDB Id:
2050532-2
SSG:
15,3
